Physician profile
Mohammad Faiz
NPI 1306661459
$3,891.46
in general payments reported to CMS, 2019-2025
18 companies · $3,853 in 2025
The $3,853 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $38.73 · 2025: $3,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.47 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.84 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $463.07 | 2025 | Cobenfy |
| Abbvie INC. | $454.11 | 2025 | |
| Lundbeck LLC | $334.99 | 2024-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $259.64 | 2025 | Auvelity |
| Alkermes, INC. | $250.69 | 2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $246.61 | 2024-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $230.67 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $218.91 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $184.07 | 2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $177.80 | 2025 | |
| Corium, LLC | $159.84 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $153.23 | 2025 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $107.92 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $74.96 | 2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $54.99 | 2025 | |
| Vanda Pharmaceuticals INC. | $28.59 | 2025 | Fanapt |
| Neos Therapeutics, Lp | $22.53 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Faiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.